These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 22744770)

  • 1. Pregnancy outcome and management of women with an implantable cardioverter defibrillator: a single centre experience.
    Schuler PK; Herrey A; Wade A; Brooks R; Peebles D; Lambiase P; Walker F
    Europace; 2012 Dec; 14(12):1740-5. PubMed ID: 22744770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Primary prevention of sudden cardiac death by implantable cardioverter-defibrillator therapy in Chinese patients with heart failure: a single-center experience.
    Chen TB; Cheng KA; Gao P; Cheng ZW; Fan JB; Jiang XC; Fang Q
    Chin Med J (Engl); 2010 Apr; 123(7):848-51. PubMed ID: 20497676
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Implantable cardioverter-defibrillators in patients with hypertrophic cardiomyopathy -- dilemmas and difficulties.
    Przybylski A; Małecka L; Pytkowski M; Chojnowska L; Lewandowski M; Sterliński M; Maciag A; Ruzyłło W; Szwed H
    Kardiol Pol; 2005 Oct; 63(4):391-7; discussion 398. PubMed ID: 16273479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Device complications and inappropriate implantable cardioverter defibrillator shocks in patients with hypertrophic cardiomyopathy.
    Lin G; Nishimura RA; Gersh BJ; Phil D; Ommen SR; Ackerman MJ; Brady PA
    Heart; 2009 May; 95(9):709-14. PubMed ID: 19282314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pregnancy in women with an implantable cardioverter-defibrillator: is it safe?
    Boulé S; Ovart L; Marquié C; Botcherby E; Klug D; Kouakam C; Brigadeau F; Guédon-Moreau L; Wissocque L; Meurice J; Lacroix D; Kacet S
    Europace; 2014 Nov; 16(11):1587-94. PubMed ID: 24596396
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The ICD for primary prevention in patients with inherited cardiac diseases: indications, use, and outcome: a comparison with secondary prevention.
    Olde Nordkamp LR; Wilde AA; Tijssen JG; Knops RE; van Dessel PF; de Groot JR
    Circ Arrhythm Electrophysiol; 2013 Feb; 6(1):91-100. PubMed ID: 23275262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single-center experience with implantable cardioverter-defibrillators in adults with complex congenital heart disease.
    Khanna AD; Warnes CA; Phillips SD; Lin G; Brady PA
    Am J Cardiol; 2011 Sep; 108(5):729-34. PubMed ID: 21684513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implantable cardioverter defibrillator therapy for prevention of sudden cardiac death in children in the Netherlands.
    Heersche JH; Blom NA; van de Heuvel F; Blank C; Reimer AG; Clur SA; Witsenburg M; ten Harkel AD
    Pacing Clin Electrophysiol; 2010 Feb; 33(2):179-85. PubMed ID: 20025697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implantable cardioverter defibrillator (ICD) in children.
    Eicken A; Kolb C; Lange S; Brodherr-Heberlein S; Zrenner B; Schreiber C; Hess J
    Int J Cardiol; 2006 Feb; 107(1):30-5. PubMed ID: 16337494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Results of a multicenter retrospective implantable cardioverter-defibrillator registry of pediatric and congenital heart disease patients.
    Berul CI; Van Hare GF; Kertesz NJ; Dubin AM; Cecchin F; Collins KK; Cannon BC; Alexander ME; Triedman JK; Walsh EP; Friedman RA
    J Am Coll Cardiol; 2008 Apr; 51(17):1685-91. PubMed ID: 18436121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison between atrial fibrillation-triggered implantable cardioverter-defibrillator (ICD) shocks and inappropriate shocks caused by lead failure: different impact on prognosis in clinical practice.
    Kleemann T; Hochadel M; Strauss M; Skarlos A; Seidl K; Zahn R
    J Cardiovasc Electrophysiol; 2012 Jul; 23(7):735-40. PubMed ID: 22313314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors predisposing to ventricular tachyarrhythmia leading to appropriate ICD intervention in patients with coronary artery disease or non-ischaemic dilated cardiomyopathy.
    Lelakowski J; Piekarz J; Rydlewska A; Majewski J; Senderek T; Ząbek A; Małecka B
    Kardiol Pol; 2012; 70(12):1264-75. PubMed ID: 23264245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The long-term survival and the risks and benefits of implantable cardioverter defibrillators in patients with hypertrophic cardiomyopathy.
    O'Mahony C; Lambiase PD; Quarta G; Cardona M; Calcagnino M; Tsovolas K; Al-Shaikh S; Rahman SM; Arnous S; Jones S; McKenna W; Elliott P
    Heart; 2012 Jan; 98(2):116-25. PubMed ID: 21757459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy.
    Maron BJ; Shen WK; Link MS; Epstein AE; Almquist AK; Daubert JP; Bardy GH; Favale S; Rea RF; Boriani G; Estes NA; Spirito P
    N Engl J Med; 2000 Feb; 342(6):365-73. PubMed ID: 10666426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Short-term and long-term outcome of left heart function after cardioverter defibrillator implantation].
    Takeichi K; Kasanuki H; Ohnishi S; Endoh Y; Hosoda S
    J Cardiol; 1996 Nov; 28(5):277-86. PubMed ID: 8953401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risks and challenges of implantable cardioverter-defibrillators in young adults.
    Sherrid MV; Daubert JP
    Prog Cardiovasc Dis; 2008; 51(3):237-63. PubMed ID: 19026858
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary prevention with defibrillator therapy in women: results from the Sudden Cardiac Death in Heart Failure Trial.
    Russo AM; Poole JE; Mark DB; Anderson J; Hellkamp AS; Lee KL; Johnson GW; Domanski M; Bardy GH
    J Cardiovasc Electrophysiol; 2008 Jul; 19(7):720-4. PubMed ID: 18373605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The implantable cardioverter-defibrillator and hypertrophic cardiomyopathy. Experience at three centers].
    Marín F; Gimeno JR; Payá E; García-Alberola A; Pérez-Alvarez L; Fernández X; de la Morena G; Sogorb F; Castro-Beiras A; Valdés M; Martínez JG; Monserrat L
    Rev Esp Cardiol; 2006 Jun; 59(6):537-44. PubMed ID: 16790196
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Left ventricular ejection fraction and absence of ACE inhibitor/angiotensin II receptor blocker predicts appropriate defibrillator therapy in the primary prevention population.
    Obeyesekere MN; Chan W; Stub D; Prabhu S; Teo EP; Toogood G; Mariani J; Broughton A; Kistler PM
    Pacing Clin Electrophysiol; 2010 Jun; 33(6):696-704. PubMed ID: 20059719
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The implantable cardioverter-defibrillator: the Portuguese experience].
    Adragão P; Neves J; Sousa J; Fançoni J; da Silva N; Antunes E; Elvas L; Bernardo J
    Rev Port Cardiol; 1997 Apr; 16(4):367-74, 351-2. PubMed ID: 9254126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.